Australia markets open in 2 hours 10 minutes

Benitec Biopharma Inc. (BNTC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3434+0.0247 (+7.75%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3187
Open0.3200
Bid0.3423 x 4000
Ask0.3640 x 1000
Day's range0.3187 - 0.3449
52-week range0.3010 - 3.9000
Volume106,286
Avg. volume331,630
Market cap8.863M
Beta (5Y monthly)1.25
PE ratio (TTM)N/A
EPS (TTM)-2.1720
Earnings date14 Nov 2022 - 18 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.00
  • GlobeNewswire

    Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

    HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced it closed its previously announced underwritten public offering of 29,809,471 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying

  • GlobeNewswire

    Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering

    HAYWARD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the pricing of its underwritten public offering of 29,809,471 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purc

  • GlobeNewswire

    Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update

    HAYWARD, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year ended June 30, 2022. The Company has filed its annual report on Form 10-K for the quarter ended June 30, 2022, with the U.S. Securities and Exchange C